Gene Therapy of Cancer
Cancer gene therapy is rapidly moving from the laboratory to the clinic. A continuous flow of laboratory results are leading to novel cancer therapeutic programmes. This text describes both the laboratory and preclinical studies and the clinical opportunities that are being developed at the end of the 20th century. It describes multiple modalities of treatment and multiple methods used to transfer anti-cancer genes into cancer cells, and to protect normal cells from cancer treatments.
- Hardback | 625 pages
- 162.56 x 241.3 x 22.86mm | 566.99g
- 01 Oct 1998
- Elsevier Science Publishing Co Inc
- Academic Press Inc
- San Diego, United States
- colour illustrations, b&w illustrations
Table of contents
Genetic and immunologic targets for gene therapy - tumour suppressor genes as targets for cancer gene therapy; characterization of specific genetic alterations in cancer cells; immunologic targets for the gene therapy of cancer; vectors and engineered products for cancer therapy; retroviral vector design for cancer gene therapy; non-infectious gene transfer and expression systems for cancer gene therapy; parvovirus vectors for the gene therapy of cancer; antibody-targeted gene therapy; cytokine gene therapy using in situ injection of vaccinia virus vectors; ribazymes in cancer gene therapy; manipulating drug effects through gene therapy - in situ use of suicide genes for cancer therapy; transfer of drug resistance genes into haematopoietic progenitors; cytosine deaminase as a suicide gene in cancer therapy; preemptive and therapeutic uses of suicide genes for cancer and leukaemia; targeting oncogenes and growth for gene therapy - gene therapy in vivo of hepatocellular and liver-metastatic colorectal cancer; antisense strategies in the treatment of leukemias; selective replicating viruses as therapeutic against cancer; molecular vaccine strategies for cancer oncogene products as tumours-specific antigens for activation of T-lymphocyte-mediated immunity; polynucleotide-mediated immunization; theory of cancer; DNA and dendritic cell-based immunization against cancer; genetically modified cells for immunization - engineering cellular cancer vaccines - gene and protein transfer options; cancer gene therapy by direct gene transfer of plasmid DNA in cationic lipids; ex vivo and in vivo cytoreductive gene therapy for urologic cancers - translation of molecular pharmacology to clinical pharmacology; applications for gene transfer in the adoptive immunotherapy of cancer; cytokine gene therapy of cancer; genetically modified effector cells for immune based immunotherapy -the use of genetically modified haematopoietic stem cells for cancer therapy; novel artificial tumour-specific killer cell and intrabody approaches for cancer therapy.